ERBB2 E401G

CI-VAR-00000733Explore in graph →CIViC 4589

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm of Unknown Primary1
ERBB2 E401G	(oncogenic)	Oncogenic	D	Supports Oncogenicity	2	submitted	EID11580 H460 cells expressing the variant were tested to evaluate phosphorylation of the downstream signalling pathway. Results show an elevation in ERK phosphorylation similar to the positive control (S310F)… (full text at CIViC) PMID 34997908 · Harada et al., 2022 · Open in CIViC	civic
Unmapped disease1unmapped disease
ERBB2 E401G	(functional)	Functional	D	Supports Gain Of Function	2	submitted	EID11579 The variant did not show the formation of disulfide-linked dimers in NTH3T3 cells compared to WT with similar results as the positive control (S310F) (Figure. 2a) . Also, the variant increased phospho… (full text at CIViC)

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.